$220.65 meals Payment -- Gilead Sciences to Dr. Mark Perez
Gilead Sciences provides $220.65 in meals to Pulmonologist Mark Perez for Ibrance
This page provides a detailed analysis of a $220.65 meals payment from Gilead Sciences to Dr. Mark Perez. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $220.65 |
| Payment Type | meals |
| Payment Nature | Food and Beverage |
| Pharmaceutical Company | Gilead Sciences |
| Physician | Dr. Mark Perez |
| NPI Number | 1765265012 |
| Physician Specialty | Pulmonology |
| Location | Springfield, IL |
| Date of Payment | 2026-04-02 |
| Related Drug/Device | Ibrance |
| Conflict Assessment | Low -- Routine |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Gilead Sciences made a $220.65 meals payment to Mark Perez, a Pulmonology specialist in Springfield, IL. The payment was associated with Ibrance. The payment of $220.65 to Dr. Mark Perez from Gilead Sciences for meals related to Ibrance is a relatively small amount. This payment occurred on April 2, 2026, indicating a recent interaction. The payment was for 'Food and Beverage', specifically meals, which is a common type of payment in the Open Payments program.
Patient Guidance: What This Payment Means for You
This payment was for meals provided by a pharmaceutical company, which may have been in connection with discussions about a medication. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for meals are common in the pharmaceutical industry, and this amount is generally considered low compared to other types of payments.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act provisions of the Affordable Care Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- gilead-sciences
- mark-perez
- pulmonology
- ibrance
- meals
- food-and-beverage
Understanding meals Payments
Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.
Frequently Asked Questions About This Payment
What was this $220.65 payment for?
This was a meals payment of $220.65 from Gilead Sciences to Mark Perez, categorized as "Food and Beverage". It was associated with Ibrance. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Mark Perez accept pharmaceutical money?
Yes, Mark Perez received this $220.65 payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Mark Perez's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this meals payment?
A meals payment of $220.65 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Pulmonology?
To compare this payment against Pulmonology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pulmonology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Mark Perez's relationship with Gilead Sciences?
The payment amount is below the average for meals and entertainment in the pharmaceutical industry. This $220.65 meals payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Pulmonology?
The specific drug mentioned, Ibrance, is an oncology drug, which may indicate the patient population discussed.
What should patients do after learning about this payment?
This payment was for meals provided by a pharmaceutical company, which may have been in connection with discussions about a medication.
What else should I know about this meals payment?
The payment date is in the future, suggesting this might be a pre-scheduled or anticipated event.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.